Abstract:As a contribution to the development of new dual/multifunctional drugs, a novel therapeutical scaffold merging key structural features from memantine and M30D was designed, synthesized, and explored for its AChE/BuChE inhibitory activity and neuroprotective effects. All synthetized hybrids were not able to inhibit AChE, but most of them exhibit inhibition with high selectivity toward butyrylcholinesterase (BuChE). Notably, among the tested compounds, amantadine/M30D hybrids with six, seven, nine, and twelve methylene groups in the spacer (5d, 5e, 5f, and 5g) not only highlighted having the best potency and selective butyrylcholinesterase inhibition greater than 83% but also, particularly 5e and 5d, elicited considerable neuroprotection when evaluated in pretreatment conditions, by reducing injury effects caused by glutamate with maximum protection reached about 47.82 ± 0.81% (5e) and 42 ± 2.20% (5d) in comparison with memantine (37.27 ± 2.69%). Likewise, we chose 5e as the hit compound, which in a glutamate excitotoxity coculture model prevented astroglia reactivity and neuronal death, as well as a 91% restoration of calcium levels and an increasing ATP level in both pre-/post-treatments of 61.48 ± 4.60 and 45.16 ± 10.55%, respectively. Regarding docking studies, a blockade of the NMDA channel pore by 5e would explain its neuroprotective response. Finally, the hit compound 5e exhibited in vitro blood-brain barrier (BBB) permeability and human plasma stability, as well as an optimal in silico neuropharmacokinetic profile. From a therapeutic perspective, merging key pharmacophoric features from memantine and M30D provides a new medicinal scaffold with dual-/multifunctional properties and human plasma stability for the future development of potential drugs for treating AD.

Synthesis of New Conjugates of Edaravone and 1-Aminoadamantanes and Their Interaction with NMDA Receptors in Rats

The Pharmacology of Aminoadamantane Nitrates.

Edaravone N-benzyl pyridinium derivatives: BACE-1 inhibition, kinetics and in silico binding pose determination

Synthesis of novel aryl-substituted 2-aminopyridine derivatives by the cascade reaction of 1,1-enediamines with vinamidinium salts to develop novel anti-Alzheimer agents

Design, synthesis, and neuroprotective effects of novel hybrid compounds containing edaravone analogue and 3-<i>n</i>-butylphthalide ring-opened derivatives

NMDA receptor antagonists. A new therapeutic approach for Alzheimer's disease.

Novel Hybrids of 3-N-butylphthalide and Edaravone: Design, Synthesis and Evaluations As Potential Anti-Ischemic Stroke Agents

Edaravone and its clinical development for amyotrophic lateral sclerosis

Neuroprotection of Oral Edaravone on Middle Cerebral Artery Occlusion in Rats

Synthesis and biological evaluation of aryloxyacetamide derivatives as neuroprotective agents.

Synthesis of N-pyrimidinyl-2-phenoxyacetamides As Adenosine A2A Receptor Antagonists

Synthesis and biological evaluation of memantine nitrates as a potential treatment for neurodegenerative diseases.

Investigation of the structural requirements for N-methyl-D-aspartate receptor positive and negative allosteric modulators based on 2-naphthoic acid

Synthetic phenylethanoid glycoside derivatives as potent neuroprotective agents.

Novel Multipotent Amantadine-M30D Hybrids with Highly Selective Butyrylcholinesterase Inhibition and Neuroprotective Effects as Effective Anti-Alzheimer's Agents

Arylazanylpyrazolone Derivatives As Inhibitors of Mutant Superoxide Dismutase 1 Dependent Protein Aggregation for the Treatment of Amyotrophic Lateral Sclerosis.

Theoretical study on the structure of edaravone and its derivatives

Design, Synthesis and Biological Evaluation of Dual-Function Inhibitors Targeting NMDAR and HDAC for Alzheimer's Disease.

Structural Analysis, Molecular Modelling and Preliminary Competition Binding Studies of AM-DAN as a NMDA Receptor PCP-Site Fluorescent Ligand

Memantine-sulfur containing antioxidant conjugates as potential prodrugs to improve the treatment of Alzheimer's disease

Post-hoc analyses of the edaravone clinical trials Study 16 and Study 19: a step toward more efficient clinical trial designs in amyotrophic lateral sclerosis